Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CCCC

C4 Therapeutics Inc

Dec 12 • 04:00PM ET

4.32

Dollar change -0.39
Percentage change -8.28	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX MRNA BGNE CRSP BNTX INCY EXEL NTLA EDIT

| Held by: VTI IWM XBI VXF IWN VTWO SCHA DFAT IWC DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.70	Insider Own	19.37%	Shs Outstand	70.56M	Perf Week	10.77%
Market Cap	304.94M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	0.00%	Shs Float	56.92M	Perf Month	-21.60%
Income	-105.50M	PEG	-	EPS next Q	-0.49	Inst Own	83.28%	Short Float	14.03%	Perf Quarter	-32.92%
Sales	33.67M	P/S	9.06	EPS this Y	42.88%	Inst Trans	7.33%	Short Ratio	7.20	Perf Half Y	-10.19%
Book/sh	3.44	P/B	1.26	EPS next Y	-3.02%	ROA	-29.76%	Short Interest	7.99M	Perf Year	84.62%
Cash/sh	3.62	P/C	1.19	EPS next 5Y	22.30%	ROE	-46.00%	52W Range	1.76 - 11.88	Perf YTD	-23.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-34.69%	52W High	-63.64%	Beta	2.93
Dividend TTM	-	Quick Ratio	6.31	Sales past 5Y	7.65%	Gross Margin	76.78%	52W Low	145.45%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	6.31	EPS Y/Y TTM	38.02%	Oper. Margin	-347.20%	RSI (14)	44.76	Volatility	16.24% 10.25%
Employees	145	Debt/Eq	0.28	Sales Y/Y TTM	65.45%	Profit Margin	-313.35%	Recom	1.89	Target Price	14.50
Option/Short	Yes / Yes	LT Debt/Eq	0.25	EPS Q/Q	35.51%	Payout	-	Rel Volume	1.40	Prev Close	4.71
Sales Surprise	160.97%	EPS Surprise	7.65%	Sales Q/Q	38.75%	Earnings	Oct 31 BMO	Avg Volume	1.11M	Price	4.32
SMA20	1.08%	SMA50	-16.95%	SMA200	-29.94%	Trades		Volume	1,553,667	Change	-8.28%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Initiated	Stephens	Equal-Weight	$4
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral	$6
Dec-13-23	Upgrade	Stifel	Hold → Buy	$2 → $12
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45
Jun-04-21	Initiated	H.C. Wainwright	Buy	$63
Mar-31-21	Initiated	BMO Capital Markets	Outperform	$55
Oct-28-20	Initiated	UBS	Buy	$44
Oct-27-20	Initiated	Jefferies	Buy	$34
Oct-27-20	Initiated	BMO Capital Markets	Outperform	$33

Show Previous Ratings

Dec-08-24 12:30PM	C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader (GlobeNewswire)
Nov-20-24 07:00AM	C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Nov-06-24 07:00AM	C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial (GlobeNewswire)
Nov-05-24 09:00AM	C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.58%
07:05AM	PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer (Business Wire)
08:20AM	Loading…
Oct-31-24 08:20AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-28-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 04:01PM	C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. (GlobeNewswire) +7.14% +11.11%
Oct-09-24 07:00AM	C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit (GlobeNewswire)
Sep-30-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-24 10:00AM	C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-10-24 07:00AM	C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen (GlobeNewswire) +13.79%
Sep-08-24 06:05PM	C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-03-24 07:00AM	C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors (GlobeNewswire)
07:00AM	Loading…
Aug-29-24 07:00AM	C4 Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 07:00AM	C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation (GlobeNewswire)
Aug-01-24 08:10AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-17-24 07:13AM	C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock? (Zacks) -7.05%
Jul-16-24 04:01PM	C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 (GlobeNewswire) +13.71%
Jul-09-24 12:00PM	C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why (Zacks) +12.87%
Jul-08-24 07:00AM	C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day (GlobeNewswire)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-10-24 07:00AM	C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors (GlobeNewswire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-10-24 02:52PM	C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations (GuruFocus.com) -9.41%
May-09-24 10:52AM	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating (MT Newswires) +5.43%
May-08-24 02:53PM	C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates (MT Newswires) -5.01%
01:54PM	CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Loading…
07:00AM	C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 07:00AM	C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum (GlobeNewswire)
Apr-08-24 08:00AM	C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-28-24 04:36AM	Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) (Insider Monkey)
Mar-05-24 04:30PM	C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 07:00AM	C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins (GlobeNewswire)
Feb-22-24 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.38%
07:36AM	C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-15-24 10:19AM	C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store? (Zacks) +8.07%
10:00AM	C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Jan-11-24 11:44AM	C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn (Zacks) -5.97%
Jan-09-24 06:20PM	C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +6.90% +5.77%
04:01PM	C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire)
Jan-04-24 04:01PM	C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals (GlobeNewswire) +9.69%
07:00AM	C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-24 11:10AM	C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why (Zacks) -11.35%
Jan-01-24 09:55AM	Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High? (Zacks)
Dec-27-23 07:35PM	11 Hot Healthcare Stocks To Buy Now (Insider Monkey) +17.54%
Dec-15-23 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet (Zacks)
Dec-13-23 12:39PM	C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck (Zacks) +135.47%
Dec-12-23 04:01PM	C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +98.31%
10:13AM	Why Is C4 Therapeutics (CCCC) Stock Up 72% Today? (InvestorPlace)
07:00AM	C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) (GlobeNewswire)
Nov-28-23 07:00AM	C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Nov-20-23 07:00AM	C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment (GlobeNewswire) -6.63%
Nov-13-23 09:55AM	Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing (Zacks)
Nov-01-23 11:03AM	C4 Therapeutics discontinues cancer program, waits for Betta payment (FierceBiotech.com) -11.41%
09:40AM	C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-11-23 07:00AM	C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC Degrader in Development for Multiple Myeloma and Non-Hodgkin's Lymphoma (GlobeNewswire)
Sep-05-23 04:01PM	C4 Therapeutics Announces Chief Financial Officer Succession (GlobeNewswire) -7.29% -10.86%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-08-23 08:40AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-04-23 06:58AM	With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big guns (Simply Wall St.)
Jul-17-23 07:00AM	C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-23 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer (GlobeNewswire) +17.31%
Jun-20-23 07:00AM	C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer (GlobeNewswire) -7.72%
May-30-23 07:00AM	C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC (GlobeNewswire) +8.77%
May-14-23 08:06AM	Broker Revenue Forecasts For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher (Simply Wall St.)
May-04-23 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire)
Apr-11-23 09:35AM	Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC) (Zacks)
Mar-23-23 07:39AM	Insiders who bought this year lost US$59k as C4 Therapeutics, Inc. (NASDAQ:CCCC) sheds US$27m in value (Simply Wall St.)
Feb-24-23 05:38AM	C4 Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) -11.46%
Feb-23-23 08:35AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-23 07:00AM	C4 Therapeutics to Present at Two Virtual February 2023 Conferences (GlobeNewswire) -5.86%
Jan-30-23 07:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF V600 Mutant Solid Tumors (GlobeNewswire)
Jan-09-23 07:00AM	C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire) +6.40%
Jan-05-23 06:15PM	C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know (Zacks)
Jan-04-23 09:40AM	Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year? (Zacks)
Jan-03-23 07:00AM	C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.14%
Nov-13-22 07:13AM	The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable (Simply Wall St.)
Nov-08-22 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet (Zacks)
Nov-03-22 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-02-22 10:01AM	C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.27%
Oct-03-22 09:02AM	One C4 Therapeutics, Inc. (NASDAQ:CCCC) insider upped their stake in the previous year (Simply Wall St.)
Sep-29-22 07:00AM	C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF-V600 Mutant Solid Cancers (GlobeNewswire) -5.01%
Sep-26-22 07:00AM	C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-06-22 08:22AM	With 63% ownership of the shares, C4 Therapeutics, Inc. (NASDAQ:CCCC) is heavily dominated by institutional owners (Simply Wall St.)
Aug-10-22 06:05AM	Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 16% (Simply Wall St.)
Aug-07-22 08:21AM	Analysts Are Upgrading C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its Latest Results (Simply Wall St.)
Aug-04-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.95%
08:00AM	C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-22 08:00AM	C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors (GlobeNewswire) +6.01%

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Salter Malcolm	Director	Nov 18 '24	Proposed Sale	4.19	13,000	54,532	Nov 18 04:43 PM
Salter Malcolm	Director	Oct 18 '24	Proposed Sale	6.41	13,000	83,321	Oct 18 04:45 PM
Salter Malcolm	Director	Oct 11 '24	Proposed Sale	5.38	8,561	46,061	Oct 11 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CCCC

C4 Therapeutics Inc

Upgrade your FINVIZ experience